News About: Pharm. Industry
Simultaneous inspections on illegal rebates
Inspection agencies have conducted inspections simultaneously in the pharmaceutical field. It is surprising that areas and subjects of the inspections vary, such as the Public Prosecutors’ Office, National Police Agen...
Was the miscarriage intention or mistake? Struggles between KCDC and GSK
In the bidding process of cervical cancer vaccines for the National Immunization Program, conflicts have been made between the Korea Centers for Disease Control and Prevention(KCDC) and GSK.
They have different opini...
Domestic pharmaceutical companies at international symposiums
Hanmi Pharm has attracted interests as announcing the clinical trial result of ‘Olita(generic name: olmutinib),’ a targeted therapy drug for lung cancer, at major academia conferences, such as 2014/2015 ASCO(American ...
Do foreign companies only launch new drugs?
Foreign pharmaceutical companies have begun to jump into the incrementally modified drug market which domestic ones have first entered to.
Since the general idea – originals come from foreign companies and modified ...
Boryung-Lilly jointly sell weekly GLP-1 analogue, ‘Trulicity’On the 7th, Boryung Pharm(CEO Tae-hong Choi) and Lilly Korea(CEO Paul Henry Huibers) announced conclusion of the joint sales agreement for domestic marketing and sales of ‘Truli...
|
Domestic pharmaceuticals conclude technology export contracts of KRW 9.3 trillion
It was observed the size of domestic pharmaceutical companies’ contracts for foreign technology exports exceeded KRW 9 trillion last year. Since the size does not include 8 of the total number of contracts, the total ...
Brilinta’s patent nullification competition fueled even more among pharmaceutical companies
While domestic pharmaceutical companies are competing over the patent nullification of the AstraZeneca’s antithrombotic, ‘Brilinta,’ the recent establishment of many claims for the patent is expected to solidify the c...
Amgen Korea, “We will focus on successful launches of products returned”Amgen Korea announced plans to focus on the domestic settlement of 3 products acquired from GSK.
The company shared future goals and plans to enter the Korean market on Februar...
|
Hanmi and Hanlim to win patent suit against Cipla, protecting their complexes
Hanmi Pharm and Hanlim Pharm won a patent suit against an Indian generic company, ‘Cipla.’
Conclusion of the suit has urgently attracted the industry since it was related to Hanmi Pharm and Hanmil Pharm’s self-develo...
Foreigner-owned stock ratios exceeded 10% in 14 listed pharmaceutical companies
It was observed stocks of a pharmaceutical company which was invested the most by foreigners were Yuhan Corporation’s.
According to the Yakup Shinmoon’s(www.yakup.com) analysis result of the foreigner-owned share sta...
